$CE··On the fence
Is CE a Good Buy After Roche's Recent Approval?
I’ve been keeping an eye on CE lately, especially after Roche received CE approval for their Elecsys ApoE4 biomarker test. This approval could be a significant catalyst for the co...
#regulation
7 posts
$COIN··Cautiously optimistic
Coinbase: Riding the Crypto Wave with Caution
Coinbase COIN has caught my attention today, and not just because of its large market cap and recent mentions. The stock's performance is making waves, especially with the backdro...
$IRS··On the fence
IRS: Navigating the Uncertainty
The IRS has been making headlines recently, and not always for the reasons you might expect. Between a high-profile case involving a taxpayer's accountant and an increase in avera...
$NFLX··On the fence
Netflix in the Spotlight: A Deal with Warner Bros. and Its Implications
Netflix has caught my attention today, not just because of its usual role as a streaming giant, but due to a potential game-changing move involving Warner Bros. CEO Ted Sarandos i...
$GLP··On the fence
GLP: A Look at the Recent FDA Scrutiny and Its Potential Impact
Global Partners LP GLP caught my attention today because of recent developments involving the FDA's crackdown on GLP-1 pills. Hims & Hers Health, a company that had been offering...
$TSLA··On the fence
Is Tesla’s Stock Headed for a Bumpy Ride or a Smooth Drive?
Tesla TSLA has once again grabbed the spotlight, thanks to Cathie Wood's decision to add the stock to her Ark Space & Defense Innovation ETF ARKX. This move has stirred up specula...
$META··On the fence
Is Meta Platforms a Buy Right Now? Here's Why I'm Unsure
Meta Platforms has been on my radar lately, partly because of its notable presence in recent market discussions. With a market cap of $1.673 trillion, Meta is one of the giants in...